PCM
GPCR icon

Prelude Capital Management’s Structure Therapeutics GPCR Stock Holding History

Prelude Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,070
Closed -$354K – 1249
2025
Q2 		$354K Sell
17,070
-8,558
-33% -$188K 0.03% 551
2025
Q1 		$444K Sell
25,628
-6,372
-20% -$156K 0.03% 550
2024
Q4 		$868K Buy
32,000
+7,023
+28% +$249K 0.05% 431
2024
Q3 		$1.1M Buy
+24,977
New +$966K 0.07% 362
2024
Q1 		– Sell
-13,700
Closed -$558K – 1395
2023
Q4 		$558K Buy
13,700
+500
+4% +$28.7K 0.04% 466
2023
Q3 		$666K Buy
+13,200
New +$425K 0.04% 396

Other funds holding GPCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Prelude Capital Management's GPCR Position: Q3 2025 in Review

Prelude Capital Management sold out of Structure Therapeutics (GPCR) in Q3 2025, closing a stake of 17,070 shares — an estimated $354K sold.

Prelude Capital Management first reported a position in GPCR in Q3 2023 and held it in 6 quarters. The position peaked at $1.1M in Q3 2024. 156 funds tracked by Wall St. Rank hold GPCR as of Q3 2025.

  • Prelude Capital Management reported no remaining Structure Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 17,070 Structure Therapeutics shares in Q3 2025, an estimated $354K.
  • Prelude Capital Management first reported a position in Structure Therapeutics in Q3 2023 and held it in 6 quarters.
  • Prelude Capital Management's Structure Therapeutics position peaked at $1.1M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.